NasdaqGM:OCULPharmaceuticals
Ocular Therapeutix (OCUL) Is Down 5.3% After Mixed SOL-1 AXPAXLI Data Disclosure Has The Bull Case Changed?
Ocular Therapeutix recently reported topline results from its SOL-1 Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, a disclosure that has triggered investor scrutiny and a law firm’s review of potential securities law compliance.
The company is now preparing detailed SOL-1 data presentations and multiple investor events, signaling that how it communicates and contextualizes these results could materially influence perceptions of AXPAXLI’s clinical profile and...